Hospital
Baystate Medical Center INC
Baystate Medical Center INC was paid $40.55M by Medicaid between Jan 2018 and Dec 2024, across 325 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 18% of everything it billed.
33Billing provider infoBAYSTATE MEDICAL CENTER INC
SPRINGFIELD, MA 01199
SPRINGFIELD, MA 01199
33aNPI1568488450assigned 07/14/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$40.55M
24GClaims3,844,354
24DCodes billed325
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#27 of 66
Median peer was paid$29.11M
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 609,102 | $5.00M | |
| 2019 | 145,133 | $1.16M | |
| 2020 | 610,041 | $6.91M | |
| 2021 | 815,716 | $10.12M | |
| 2022 | 803,128 | $8.60M | |
| 2023 | 732,007 | $7.43M | |
| 2024incomplete | 129,227 | $1.33M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 18% | 114,112 | 105,170 | $7.26M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 5.0% | 81,324 | 78,540 | $2.01M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.9% | 80,396 | 77,660 | $1.98M |
| 84443 | Thyroid stimulating hormone (TSH) | 3.1% | 129,296 | 125,892 | $1.24M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.6% | 65,210 | 63,831 | $1.05M |
| 81513 | 2.5% | 16,755 | 15,424 | $1.03M | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 2.4% | 61,936 | 60,733 | $981K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 2.2% | 3,094 | 3,046 | $912K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.2% | 50,829 | 47,115 | $904K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.2% | 28,136 | 24,520 | $873K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 184,336 | 171,921 | $782K |
| 87631 | 1.8% | 7,465 | 7,360 | $736K |
313 more codes
| 86480 | 1.6% | 16,875 | $665K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.5% | 26,785 | $612K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.5% | 119,676 | $607K |
| 87481 | 1.5% | 19,670 | $602K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.4% | 25,384 | $578K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1.3% | 27,136 | $542K |
| 86780 | 1.1% | 50,092 | $453K | |
| 86803 | 1.1% | 49,460 | $447K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 1.1% | 6,016 | $432K |
| 80053 | Comprehensive metabolic panel | 1.0% | 152,351 | $423K |
| 86003 | 1.0% | 17,883 | $412K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.0% | 9,602 | $408K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 75,411 | $396K |
| 87536 | <1% | 7,783 | $392K | |
| 80061 | Lipid panel | <1% | 121,421 | $381K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 12,824 | $358K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 5,103 | $345K |
| 83655 | <1% | 29,348 | $318K | |
| 85027 | <1% | 78,207 | $305K | |
| 83013 | <1% | 6,486 | $304K | |
| 82607 | <1% | 39,249 | $303K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,035 | $290K |
| 82728 | <1% | 36,993 | $288K | |
| 87902 | <1% | 1,865 | $283K | |
| 83970 | <1% | 16,647 | $283K | |
| 87088 | <1% | 34,612 | $278K | |
| 87522 | Neg quan hep c or qual rna | <1% | 9,376 | $261K |
| 84439 | <1% | 45,485 | $247K | |
| 80050 | General health panel | <1% | 8,764 | $224K |
| 87340 | <1% | 33,437 | $222K | |
| ATP17 | <1% | 31,373 | $203K | |
| 86481 | <1% | 3,931 | $199K | |
| 84702 | <1% | 16,755 | $196K | |
| ATP14 | <1% | 35,505 | $187K | |
| 86317 | <1% | 17,428 | $182K | |
| 84403 | <1% | 9,502 | $158K | |
| 81001 | <1% | 85,248 | $152K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 72,062 | $152K |
| 83550 | <1% | 32,668 | $151K | |
| 82570 | <1% | 59,718 | $148K | |
| 86360 | <1% | 5,595 | $142K | |
| 86762 | <1% | 12,694 | $139K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,190 | $136K |
| 84153 | <1% | 14,725 | $135K | |
| 83540 | <1% | 36,242 | $128K | |
| 83880 | <1% | 9,184 | $121K | |
| 82043 | <1% | 44,233 | $117K | |
| 82746 | <1% | 15,311 | $117K | |
| 87081 | <1% | 20,650 | $116K | |
| 86355 | <1% | 5,597 | $115K | |
| 86357 | <1% | 5,591 | $114K | |
| 87186 | <1% | 21,650 | $113K | |
| 86359 | <1% | 5,571 | $111K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 1,323 | $110K |
| 87077 | <1% | 22,878 | $109K | |
| 84146 | <1% | 7,676 | $102K | |
| 86704 | <1% | 14,632 | $101K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 355,921 | $101K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 3,331 | $100K |
| 86850 | <1% | 13,501 | $100K | |
| 83516 | <1% | 8,806 | $99K | |
| 82670 | <1% | 4,798 | $93K | |
| 87070 | <1% | 14,310 | $93K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,578 | $92K |
| 83001 | <1% | 6,763 | $88K | |
| 87653 | <1% | 2,993 | $87K | |
| ATP08 | <1% | 23,153 | $87K | |
| 82784 | <1% | 9,581 | $81K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 4,956 | $78K |
| 82652 | <1% | 3,264 | $78K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,524 | $77K |
| 86038 | <1% | 9,807 | $77K | |
| 85610 | <1% | 41,279 | $76K | |
| ATP15 | <1% | 13,139 | $75K | |
| 83735 | <1% | 23,946 | $73K | |
| 86787 | <1% | 7,668 | $72K | |
| 86140 | <1% | 22,314 | $72K | |
| 83718 | <1% | 13,034 | $68K | |
| 80074 | <1% | 1,885 | $67K | |
| 82274 | <1% | 8,340 | $64K | |
| 84270 | <1% | 4,623 | $63K | |
| 80069 | <1% | 24,038 | $63K | |
| 86618 | <1% | 5,732 | $62K | |
| 83002 | <1% | 4,683 | $62K | |
| 83021 | <1% | 4,280 | $60K | |
| 82105 | <1% | 4,414 | $57K | |
| 87529 | <1% | 2,031 | $56K | |
| 87480 | <1% | 3,389 | $54K | |
| 87510 | <1% | 3,375 | $54K | |
| ATP11 | <1% | 10,132 | $54K | |
| 87660 | <1% | 3,379 | $54K | |
| 87147 | <1% | 12,591 | $53K | |
| 80076 | <1% | 20,043 | $53K | |
| 86708 | <1% | 7,324 | $52K | |
| 82785 | <1% | 4,121 | $50K | |
| 83721 | <1% | 11,765 | $49K | |
| 85652 | <1% | 28,702 | $48K | |
| ATP18 | <1% | 6,976 | $48K | |
| 84460 | <1% | 30,288 | $47K | |
| 84481 | <1% | 4,532 | $46K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,351 | $45K |
| 86160 | <1% | 3,427 | $44K | |
| 86696 | <1% | 3,203 | $43K | |
| 86376 | <1% | 4,382 | $43K | |
| ATP03 | <1% | 9,318 | $42K | |
| 86665 | <1% | 1,699 | $41K | |
| 84450 | <1% | 28,293 | $41K | |
| 82565 | <1% | 25,038 | $39K | |
| 82950 | <1% | 9,611 | $38K | |
| 82627 | <1% | 2,366 | $37K | |
| 83014 | <1% | 6,441 | $35K | |
| 86235 | <1% | 1,455 | $35K | |
| 86765 | <1% | 4,049 | $34K | |
| 82951 | <1% | 3,255 | $34K | |
| 84156 | <1% | 18,008 | $34K | |
| 83690 | <1% | 7,726 | $34K | |
| 87517 | <1% | 1,330 | $32K | |
| 80197 | <1% | 7,316 | $32K | |
| 86735 | <1% | 3,761 | $32K | |
| 87209 | <1% | 2,655 | $31K | |
| 82465 | <1% | 15,739 | $31K | |
| 87046 | <1% | 2,832 | $29K | |
| 86900 | <1% | 11,532 | $29K | |
| 87338 | <1% | 2,962 | $29K | |
| ATP10 | <1% | 9,662 | $28K | |
| 83520 | <1% | 2,638 | $28K | |
| 86800 | <1% | 2,740 | $28K | |
| 82248 | <1% | 23,204 | $26K | |
| 87205 | <1% | 9,248 | $26K | |
| 82533 | <1% | 2,618 | $26K | |
| ATP07 | <1% | 5,499 | $26K | |
| 80051 | <1% | 10,453 | $26K | |
| 87507 | <1% | 104 | $26K | |
| 86901 | <1% | 11,385 | $26K | |
| 87581 | <1% | 963 | $25K | |
| 87486 | <1% | 964 | $25K | |
| 86705 | <1% | 3,843 | $25K | |
| 88304 | <1% | 651 | $23K | |
| 86431 | <1% | 6,414 | $23K | |
| 80164 | <1% | 3,754 | $23K | |
| 81025 | <1% | 4,028 | $21K | |
| 87350 | <1% | 3,467 | $21K | |
| ATP02 | <1% | 7,458 | $21K | |
| 86695 | <1% | 2,223 | $21K | |
| 81508 | <1% | 556 | $21K | |
| 87799 | <1% | 1,575 | $20K | |
| 85730 | <1% | 5,152 | $19K | |
| 86200 | <1% | 2,304 | $19K | |
| 88342 | <1% | 415 | $19K | |
| 86664 | <1% | 1,592 | $18K | |
| 84550 | <1% | 13,928 | $18K | |
| 86769 | <1% | 891 | $18K | |
| 86617 | <1% | 1,634 | $18K | |
| 82947 | <1% | 9,140 | $18K | |
| 84520 | <1% | 14,498 | $17K | |
| 82150 | <1% | 4,246 | $17K | |
| 84100 | <1% | 11,889 | $17K | |
| 86039 | <1% | 2,460 | $17K | |
| 84144 | <1% | 1,151 | $17K | |
| 88112 | <1% | 779 | $17K | |
| 82550 | <1% | 8,933 | $17K | |
| 86334 | <1% | 1,658 | $16K | |
| 87045 | <1% | 2,754 | $16K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 862 | $16K |
| ATP13 | <1% | 3,550 | $16K | |
| 85018 | <1% | 8,191 | $16K | |
| 84134 | <1% | 1,766 | $16K | |
| 86677 | <1% | 1,541 | $16K | |
| 87177 | <1% | 2,655 | $15K | |
| 86225 | <1% | 1,593 | $15K | |
| 86008 | <1% | 142 | $14K | |
| 81003 | <1% | 10,244 | $14K | |
| 87476 | <1% | 702 | $14K | |
| 84154 | <1% | 1,798 | $14K | |
| 86706 | <1% | 1,972 | $14K | |
| 87210 | <1% | 4,276 | $14K | |
| 87899 | <1% | 1,546 | $13K | |
| 83921 | <1% | 1,665 | $13K | |
| 83993 | <1% | 1,118 | $13K | |
| ATP04 | <1% | 2,769 | $12K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 454 | $12K |
| 85014 | <1% | 6,385 | $12K | |
| 82247 | <1% | 7,666 | $12K | |
| 80180 | <1% | 1,889 | $12K | |
| 36416 | <1% | 9,168 | $12K | |
| ATP16 | <1% | 2,532 | $11K | |
| 82553 | <1% | 2,598 | $11K | |
| 82952 | <1% | 3,288 | $10K | |
| 87449 | <1% | 1,802 | $10K | |
| ATP09 | <1% | 2,580 | $10K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 176 | $10K |
| 86255 | <1% | 903 | $10K | |
| 87324 | <1% | 1,741 | $9K | |
| ATP05 | <1% | 1,825 | $9K | |
| 80178 | <1% | 2,713 | $9K | |
| 84165 | <1% | 1,843 | $9K | |
| 84480 | <1% | 1,409 | $9K | |
| 85045 | <1% | 3,669 | $9K | |
| 86141 | <1% | 1,167 | $9K | |
| 82310 | <1% | 4,289 | $8K | |
| 82977 | <1% | 3,663 | $8K | |
| 83525 | <1% | 998 | $8K | |
| 84466 | <1% | 977 | $8K | |
| 84075 | <1% | 4,440 | $8K | |
| 83615 | <1% | 3,577 | $7K | |
| 87625 | <1% | 387 | $7K | |
| 85379 | <1% | 1,207 | $7K | |
| 84436 | <1% | 1,835 | $7K | |
| 0099U | <1% | 41 | $6K | |
| 84425 | <1% | 671 | $6K | |
| 86593 | <1% | 2,070 | $6K | |
| ATP06 | <1% | 1,508 | $6K | |
| 82040 | <1% | 3,306 | $6K | |
| 84163 | <1% | 442 | $6K | |
| 83883 | <1% | 618 | $6K | |
| 87206 | <1% | 1,659 | $6K | |
| 87329 | <1% | 796 | $6K | |
| 87427 | <1% | 776 | $5K | |
| 86308 | <1% | 1,249 | $5K | |
| 87563 | <1% | 261 | $5K | |
| 82677 | <1% | 284 | $5K | |
| 84402 | <1% | 271 | $4K | |
| ATP12 | <1% | 1,127 | $4K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,889 | $4K |
| 82330 | <1% | 536 | $4K | |
| 84703 | <1% | 752 | $4K | |
| 82340 | <1% | 937 | $3K | |
| 81401 | <1% | 50 | $3K | |
| 82088 | <1% | 132 | $3K | |
| 88312 | <1% | 172 | $3K | |
| 83498 | <1% | 149 | $3K | |
| 83010 | <1% | 331 | $3K | |
| 83090 | <1% | 307 | $3K | |
| 82172 | <1% | 238 | $3K | |
| 84132 | <1% | 1,628 | $3K | |
| 81050 | <1% | 1,363 | $3K | |
| 84300 | <1% | 858 | $2K | |
| 82024 | <1% | 88 | $2K | |
| 86666 | <1% | 81 | $2K | |
| 86336 | <1% | 163 | $2K | |
| 84305 | <1% | 145 | $2K | |
| 87102 | <1% | 481 | $2K | |
| 86304 | <1% | 175 | $2K | |
| ATP19 | <1% | 399 | $2K | |
| 82397 | <1% | 210 | $2K | |
| 86352 | <1% | 26 | $2K | |
| 84155 | <1% | 1,695 | $2K | |
| 80175 | <1% | 396 | $2K | |
| 82787 | <1% | 145 | $2K | |
| 80177 | <1% | 353 | $2K | |
| 84244 | <1% | 118 | $2K | |
| 82140 | <1% | 273 | $1K | |
| 80156 | <1% | 510 | $1K | |
| 86709 | <1% | 229 | $1K | |
| 88300 | <1% | 81 | $1K | |
| 85651 | <1% | 623 | $1K | |
| 85613 | <1% | 172 | $1K | |
| 86753 | <1% | 149 | $1K | |
| 84484 | <1% | 269 | $1K | |
| 85660 | <1% | 260 | $1K | |
| 86147 | <1% | 34 | $1K | |
| 83835 | <1% | 107 | $1K | |
| 84681 | <1% | 118 | $1K | |
| 84207 | <1% | 89 | $1K | |
| 87040 | <1% | 116 | $987.00 | |
| 86162 | <1% | 67 | $943.81 | |
| 84630 | <1% | 117 | $934.86 | |
| 82390 | <1% | 148 | $886.00 | |
| 84445 | <1% | 26 | $835.17 | |
| 82507 | <1% | 37 | $832.15 | |
| 86707 | <1% | 120 | $831.18 | |
| 86258 | <1% | 348 | $677.86 | |
| 82378 | <1% | 67 | $663.34 | |
| 80162 | <1% | 96 | $526.77 | |
| 82610 | <1% | 64 | $495.89 | |
| 89055 | <1% | 195 | $457.85 | |
| 84560 | <1% | 106 | $413.51 | |
| 82374 | <1% | 213 | $343.27 | |
| 80183 | <1% | 24 | $342.89 | |
| 86611 | <1% | 14 | $334.08 | |
| 80299 | <1% | 50 | $324.76 | |
| 82272 | <1% | 105 | $308.42 | |
| 82525 | <1% | 54 | $283.00 | |
| 83945 | <1% | 25 | $281.16 | |
| 86812 | <1% | 12 | $266.10 | |
| 85245 | <1% | 12 | $253.06 | |
| 84482 | <1% | 26 | $238.70 | |
| 86682 | <1% | 28 | $229.40 | |
| 82103 | <1% | 27 | $220.68 | |
| 86644 | <1% | 28 | $210.08 | |
| 81002 | <1% | 95 | $192.72 | |
| 86694 | <1% | 17 | $170.69 | |
| 85049 | <1% | 55 | $138.08 | |
| 84432 | <1% | 14 | $125.02 | |
| ATP20 | <1% | 39 | $124.74 | |
| 81015 | <1% | 61 | $121.42 | |
| 87015 | <1% | 17 | $104.98 | |
| 84540 | <1% | 42 | $94.48 | |
| 84478 | <1% | 196 | $88.40 | |
| 87075 | <1% | 30 | $87.84 | |
| 80185 | <1% | 15 | $60.45 | |
| 80158 | <1% | 13 | $55.86 | |
| 84105 | <1% | 13 | $54.20 | |
| 80159 | <1% | 20 | $53.31 | |
| 87185 | <1% | 12 | $51.96 | |
| 84133 | <1% | 16 | $44.05 | |
| 82523 | <1% | 14 | $39.45 | |
| 81596 | 0% | 194 | $0.00 | |
| 82575 | 0% | 13 | $0.00 | |
| 81511 | 0% | 110 | $0.00 | |
| 0240U | 0% | 12 | $0.00 | |
| 80373 | 0% | 71 | $0.00 | |
| 80348 | 0% | 53 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCARTHY, RAYMOND (SR. VP, CFO & TREASURER)
| Provider | Location | Paid |
|---|---|---|
| Baystate Wing Hospital Corporation | Palmer, MA | $38.22M |
| Baystate Franklin Medical Center | Greenfield, MA | $29.11M |
| Baystate Wing Hospital Corporation | Palmer, MA | $2.29M |
| Baystate Medical Center INC | Springfield, MA | $1.12M |
| Baystate Franklin Medical Center | Greenfield, MA | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.